RSS-Feed abonnieren
DOI: 10.1055/s-0038-1648415
The Predictive Value of the Hemostasis Parameters in the Development of Preeclampsia
Publikationsverlauf
Received 05. Februar 1991
Accepted after revision 09. September 1991
Publikationsdatum:
02. Juli 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/199202/lookinside/thumbnails/10-1055-s-0038-1648415-1.jpg)
Summary
In order to find out which hemostasis parameters would have the predictive value for the development of preeclampsia, modified antithrombin III (ATM, representative of the antithrombin Ill-serine esterase complex), tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), beta-throm-boglobulin (BTG), antithrombin III (AT III), fibrinogen, fibrin(ogen) degradation product (FDP), FDP D-dimer and euglobulin lysis time (ELT) were measured in 20 normal nonpregnant women, 21 normal pregnant women, 6 high-risk pregnant women, 14 preeclampsia pregnant women, and 5 patients with disseminated intravascular coagulation (DIC). Only tPA and AT III were found significantly different between the preeclampsia and the normal or high-risk pregnant women: tPA was found progressively and significantly increased from the normal pregnant, to the high-risk pregnant, then to the preeclampsia women (p <0.05). AT III was significantly lower in the preeclampsia than in the normal pregnant (p = 0.0001) or in the high-risk pregnant women (p = 0.002). In the 2nd trimester, tPA, PAI, fibrinogen and FDP were significantly higher, and AT III was significantly lower in the preeclampsia than in the normal pregnant women, whereas in the 3rd trimester, tPA and AT III were significantly higher or lower, respectively, in the preeclampsia than in the normal pregnant women. No significant difference of ATM could be found between the preeclampsia and the normal or high-risk pregnant women. From the present study, we suggest that tPA and AT III would be used as the main predictors, and FDP and D-dimer as the complementary predictors for the development of preeclampsia and should be detected in the normal or high-risk pregnant women.
-
References
- 1 Laros RK, Alger LS. Thromboembolism and pregnancy. Clin Obstet Gynecol 1979; 22: 871-888
- 2 Stirling Y, Woolf L, North WRS, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemostas 1984; 52: 176-182
- 3 Wisman B, Csemiczky G, Marsk L, Robbe H. The fast inhibitor of tissue type plasminogen activator in plasma during pregnancy. Thromb Haemostas 1984; 52: 124-126
- 4 Kobayashi T, Terao T. The role of coagulation factors in maintaining pregnancy. Thromb Haemostas 1989; 62: 156 (Abstr)
- 5 Astedt B. Haemostasis in pregnancy - The placental regulation of fibrinolysis. Thromb Haemostas 1989; 62: 155 (Abstr)
- 6 McKay DG. Chronic intravascular coagulation in normal pregnancy and preeclampsia. Contrib Nephrol 1981; 25: 108-119
- 7 Kobayashi T, Terao T. Preeclampsia as chronic disseminated intravascular coagulation. Gynecol Obstet Invest 1987; 24: 170-178
- 8 Amiral J. Evaluation of ATM (modified AT III) - a marker of blood activation. In: Thrombotic and Prethrombotic Markers - Abtract book of 6th International Symposium organized by. Diagnostica Stago; Paris: 1990. pp 21-25
- 9 Heimberger N, Pelzer H. Determination of human thrombin-antithrombin III complex by enzyme immunoassay. Folia Haematol (Leipz) 1988; 115: 269-273
- 10 Pelzer H. Thrombin/antithrombin III complex (TAT) - a new parameter for detection of thrombotic states. Rinsho Byor 1989; 91: 198-220
- 11 Contant G, Martinoli JL. Determination of plasminogen activator inhibitor (PAI) activity of human plasma after dilution in a PAI-depleted plasma. Thromb Res 1989; 56: 377-386
- 12 Odegard OR, Lie M, Abildgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res 1975; 6: 287-295
- 13 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (tPA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to tPA. Thromb Haemostas 1985; 54: 684-687
- 14 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957; 17: 237-246
- 15 Chakrabarti M, Bielawiec JF, Evans JF, Fearnley GR. Methodological study and a recommended technique for determining the euglobulin lysis time. J Clin Pathol 1968; 21: 698-701
- 16 Woodhams BJ, Candotti G, Shaw R, Kernoff PB. Changes in coagulation and fibrinolysis during pregnancy: Evidence of activation of coagulation preceding spontaneous abortion. Thromb Res 1989; 55: 99-107
- 17 Maki M. The placental regulation of blood coagulation and platelet aggregation. Thromb Haemostas 1989; 62: 155 (Abstr)
- 18 De Boer K, Ten Cate JW, Sturk A, Bom JJJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989; 160: 95-100
- 19 Estelles A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989; 74: 1332-1338
- 20 Benedetto C, Massobrio M, Bertini E, Abbondanza M, Enrieu N, Tetta C. Reduced serum inhibition of platelet-activating factor activity in preeclampsia. Am J Obstet Gynecol 1989; 160: 100-104
- 21 Hutton RA, Dandona P, Chow FPR, Craft IL. Inhibition of platelet aggregation by placental extracts. Thromb Res 1980; 17: 465-471
- 22 Bonnar J, Daly L, Sheppard B. Changes in the fibrinolytic system during pregnancy. Semin Thromb Hemostas 1990; 16: 221-229
- 23 Bonnar J, McNicol GP, Douglas AS. Coagulation and fibrinolytic systems in preeclampsia and eclampsia. Br Med J 1971; 2: 12-16
- 24 Howie PW, Prentice CRM, McNicol GP. Coagulation, fibrinolysis and placental function in preeclampsia, essential hypertension, and placental insufficiency. J Obstet Gynaecol Br Commonw 1971; 78: 992-1003
- 25 Gow L, Campbell DM, Ogston D. The fibrinolytic system in preeclampsia. J Clin Pathol 1984; 37: 56-58
- 26 Fitzgerald DJ, Rocki W, Murray R, Mayo G, Fitzgerald GA. Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet 1990; 335: 751-754
- 27 Van Geet C, Spitz B, Vermylen J, Van Assche FA. Urinary thromboxane metabolites in pre-eclampsia. Lancet 1990; 335: 1168-1169
- 28 Xu C, Zhou L, Shong S, Wang S, Zhang M, Weiner CP. Antithrombin III activity in Chinese women with preeclampsia. Thromb Res 1990; 59: 401-406